News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
dars.gov.et Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Scilex Holding Company (NASDAQ: DVLT) has updated its Schedule 13D filing, disclosing that it now beneficially owns 17.2% of Datavault AI Inc., totaling 163,766,229 common shares. This update also reveals a new $20 million uncommitted revolving line of credit agreement with Vivasor, Inc., where โฆ
Scilex Holding Co., a major shareholder in Datavault AI Inc. (DVLT), has transferred 50 million shares of DVLT common stock to Vivasor, Inc. This transaction, valued at $0.3151 per share, was not a market sale but a drawdown under a promissory note and revolving โฆ
A federal court has granted a motion to compel arbitration and stay all court proceedings in California for the case of Scilex Holding Company v. Wade et al. The court found a valid and enforceable arbitration clause in the Loan Agreement between Scilex and โฆ
Scilex Holding Co (SCLX) reported a significant net loss of $(114.7M) and diluted EPS of $(16.65) for Q2 2026, on revenue of $7.6M. This represents a widening loss and a revenue decline compared to the previous year, primarily due to shipment delays of ZTlido. โฆ
Scilex Holding Company has established an uncommitted revolving line of credit worth up to $20 million with Vivasor, Inc., as per a recent SEC filing. The agreement allows Vivasor to request advances, with Scilex having sole discretion over funding, which can be in cash, โฆ
This article reports on Scilex Holding Co's Form 8K filing for August 12. It provides the financial news without further details about the content of the filing. The article also includes market data, trending stocks, and various financial tools available on Investing.com.
Scilex Holding Co has entered into a promissory note with Vivasor for a revolving credit facility of up to $20 million. This agreement was finalized on August 8. The credit facility aims to provide financial flexibility for Scilex Holding Co.
This article provides a revenue breakdown for Scilex Holding Company (SCLXW). It highlights that the United States was the primary contributor to its revenue, accounting for $30.25 million last year and $56.59 million the year before. The data is presented from a financial overview โฆ
This article provides the enterprise value to EBIT forward for Scilex Holding Company (NASDAQ: SCLX). It highlights that the market for SCLX was closed with no trades. The information is presented within the context of financial data provided by TradingView.
This article provides a revenue breakdown for Scilex Holding Company (NASDAQ: SCLX), highlighting that the United States was the primary contributor to its revenue in the last year, bringing in $30.25 million, a decrease from $56.59 million the year prior. The data is presented โฆ
Scilex Holding Co (SCLX) is currently trading at $6.835, down 2.77%, with a market capitalization of $48.07 million. The company, focused on non-opioid pain management products, has high growth potential but weak fundamentals and is considered fairly valued in the Pharmaceuticals industry. Analysts have โฆ
This article details the shareholder structure of Scilex Holding Co (SCLX), listing both major shareholders and institutional holdings. It provides a breakdown of shareholder types, including corporations, hedge funds, and investment advisors, along with the proportion of shares held by each. The data also โฆ
This article provides a detailed quarterly and annual income statement for Scilex Holding Co (SCLX), offering insights into its financial performance and operational efficiency. It presents key financial metrics such as total revenue, cost of revenue, operating expenses, operating profit, net income, and basic/diluted โฆ
This article provides an earnings forecast for Scilex Holding Co (SCLX), noting that no earnings forecast score is currently available, while the Pharmaceuticals industry average is 7.86. One analyst has a "Hold" rating for SCLX with a target price of $490.00, suggesting a significant โฆ
This article provides a revenue breakdown for Scilex Holding Company (NASDAQ: SCLXW), highlighting its financial performance. The primary revenue contribution for the company in recent years has come from the United States, with figures of $30.25 million last year and $56.59 million the year โฆ
This article provides a revenue breakdown for Scilex Holding Company (DUS:D8B0), highlighting that the United States was the primary contributor to its revenue in both the last year and the year prior. The revenue figures are presented in Euros.
Scilex Holding Company has announced the strategic sale of over 6.4 million shares of Vivasorโs Series A-1 and A-2 preferred stock back to Vivasor Holding Company. The transaction, valued at approximately $12 million, will be paid to Scilex in multiple tranches through June 30, โฆ
Scilex (SCLX) has entered into a stock repurchase agreement to sell its previously acquired Vivasor preferred shares back to Vivasor for approximately $12.0 million. The payment will be made in five tranches from July 18, 2026, through June 30, 2027. This transaction aims to โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States